Pharmaceutical - Financial, Antibiotics and Infectious diseases


Popular Filters

New Zealand proposal for sole supply of Remicade in DHB hospitals

New Zealand proposal for sole supply of Remicade in DHB hospitals


Following a Request for Tender for infliximab issued on September 2, 2014 (RFT), New Zealand’s Pharmaceutical…

Anti-Arthritics/RheumaticsAntibiotics and Infectious diseasesceftaroline fosamilFinancialJanssen-CilagJohnson & JohnsonNew ZealandPharmaceuticalPricingRemicade

Biota tanks as flu drug candidate disappoints

Biota tanks as flu drug candidate disappoints


USA-based Biota Pharmaceuticals saw its shares slump 29% to a record low of $2.29 on Friday, after the…

Anti-viralsAntibiotics and Infectious diseasesBiota PharmaceuticalsFinancialPharmaceuticalResearchUSA

New Zealand to fund Norgine’s Xifaxan for hepatic encephalopathy

New Zealand to fund Norgine’s Xifaxan for hepatic encephalopathy


New Zealand Pharmaceutical Management Agency PHARMAC has awarded a tender to Netherlands-headquartered…

Antibiotics and Infectious diseasesFinancialHealthcareNew ZealandNorginePharmaceuticalXifaxan

Joint purchasing of vaccines and medicines becomes a reality in the EU

Joint purchasing of vaccines and medicines becomes a reality in the EU


The European Commission today approved a Joint Procurement Agreement, which will enable all European…

Antibiotics and Infectious diseasesEuropeFinancialMarkets & MarketingPharmaceuticalVaccines

MRCF invests in Australian antibiotics start-up Auspherix


Auspherix Pty, an early stage anti-infectives company developing novel antibiotics to treat resistant…

Antibiotics and Infectious diseasesAsia-PacificAuspherixAustraliaFinancialPharmaceuticalResearch

EU steps up its fight against drug-resistant bacteria


A survey published by the European Commission today (November 15) reveals a decrease in antibiotic use…

Antibiotics and Infectious diseasesEuropeFinancialPharmaceuticalResearch

$200+ billion annual opportunity in USA from using medicines more responsibly, IMS finds


Avoidable costs of more than $200 billion are incurred each year in the US health care system as a result…

Antibiotics and Infectious diseasesDiabetesFinancialGenericsHealthcareNorth AmericaPharmaceutical

Rising drug resistance driving early-line use of powerful antibiotics, according to surveyed EU5 physicians


More than half of physicians surveyed by health care advisory firm, Decision Resources from the EU5 (France,…

Antibiotics and Infectious diseasesEuropeFinancialMarkets & MarketingPharmaceutical

GlaxoSmithKline gets $200 million BARDA award to develop new antibiotics


UK pharma giant GlaxoSmithKline (LSE: GSK) and the Biomedical Advanced Research and Development Authority…

Antibiotics and Infectious diseasesFinancialGlaxoSmithKlinePharmaceuticalResearch

Actavis pays Valeant $55M for drug rights; Incyte gets $25M milestone


US generics major Actavis (NYSE: ACT), reportedly the subject of a stalled takeover bid from Canada's…

ActavisAntibiotics and Infectious diseasesFinancialGenericsINC280IncyteLicensingMetronidazole LotionNovartisOncologyPharmaceuticalResearchValeant Pharmaceuticals

New European anti-infectives company, Allecra Therapeutics, created


The creation of Allecra Therapeutics, a new company joining the established European BioValley Life Sciences…

Allecra TherapeuticsAntibiotics and Infectious diseasesFinancialOrchid Chemicals & PharmaceuticalsPharmaceuticalResearch

New executive director of the Global Fund outlines ambitious agenda


Mark Dybul yesterday took charge as executive director of the Global Fund to Fight AIDS, Tuberculosis…

Anti-viralsAntibiotics and Infectious diseasesFinancialManagementPharmaceuticalTropical diseases

NeRRe Therapeutics created to develop NRAs from GSK; GlycoVaxyn deal with GSK


NeRRe Therapeutics was launched in the UK yesterday to develop a portfolio of clinical and pre-clinical…

Antibiotics and Infectious diseasesBiotechnologyFinancialGlaxoSmithKlineGlycoVaxynLicensingNeRReTherapeuticsNeurologicalNovo NordiskPharmaceuticalResearchVaccines

Pfizer agrees $55 million settlement for off-label promotion of Protonix by Wyeth; strikes deal over Zyvox and Lyrica


USA-based Pfizer (NYSE: PFE), the world's largest drugmaker by sales, has agreed to pay $55 million plus…

Antibiotics and Infectious diseasesFinancialGastro-intestinalsLegalLyricaMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceuticalProtonixWyethZyvox

GlaxoSmithKline amends accord with Isis Pharma; gets FDA panel backing for raxibacumab


USA-based Isis Pharmaceuticals (Nasdaq: ISIS) says it has agreed to amend the clinical development plan…

Antibiotics and Infectious diseasesBiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsISIS-TTR.RXLicensingNorth AmericaPharmaceuticalRare diseasesraxibacumabRegulationResearch

Cubist unveils five-year strategic goals; enters antibiotics collaboration


USA-based Cubist Pharmaceuticals (Nasdaq: CBST) has announced its five-year strategic aspirations - Building…

Antibiotics and Infectious diseasesCubicinCubist PharmaceuticalsEnteregFinancialFundacion MEDINAPharmaceuticalResearch

Optimer earns 10 million-euro milestone as Astellas debuts Dificlir in Europe


USA-Based Optimer Pharmaceuticals (Nasdaq: OPTR) says that it is set to receive 10 million euros ($12.5…

Antibiotics and Infectious diseasesAstellas PharmaDificlirEuropeFinancialLicensingOptimer PharmaceuticalsPharmaceutical

Back to top